Comments
Aurobindo Pharma’s consolidated net profit declined 8 per cent at Rs 384 crore in the third quarter ended December 31, 2014 compared to Rs 417 crore in the corresponding quarter of the previous financial year.
The total income of the company, however, had gone up 48 per cent to Rs 3,166 crore (Rs 2140 crore).
Commenting on the Company’s performance, N Govindarajan, Managing Director of the company said: “We continue to grow our revenues and maintain profitability despite the absence of any exceptional upside.’’
The company was investing in further differentiating its product portfolio through initiation of developmental research in highly complex molecules and novel technology platforms, he added.
The board had approved second interim dividend at 200 per cent in addition to the interim dividend of 150 per cent aggregating to 350 per cent for the year 2014-15.
The company’s scrip lost 1.26 per cent on the Bombay Stock Exchange on Wednesday to close at Rs 1211.35.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.